Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facilities.
Lilly sues US agency over blocking of drug-rebate program
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals.
Eli Lilly follows JNJ in suing govt. over 340B drug-discount program
Eli Lilly (NYSE:LLY) has filed a lawsuit over a U.S. health agency's alleged attempts to block its model for offering rebates for drugs supplied under the government's 340B Program, days after its rival Johnson & Johnson (NYSE:JNJ) filed a similar lawsuit.
Eli Lilly sues to change hospital drug discount payments, WSJ reports
Eli Lilly (LLY) has filed a lawsuit against the heads of the Department of Health and Human Services and one of its agencies, seeking a court
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis.
Lilly Sues U.S. to Change Hospital Drug Discount Payments
Eli Lilly sued a federal health agency that has blocked the company’s plan to tighten the way it provides lucrative drug discounts to hospitals.Lilly is the second drugmaker this week to go to court over the issue,
Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan
Eli Lilly sued the Health Resources and Services Administration (HRSA) for allegedly blocking the pharma giant's proposal to change the manner by which it offers discounts on medicines under the 340B program.
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
5 new weight-loss drugs to watch in the fight for the next Ozempic
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
Diabetes and weight loss drugs shown to reduce alcohol-related hospitalizations, study finds
Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why diabetes and weight loss drugs work better than alcohol medications.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...
Modern Healthcare2d
340B drug rebate proposal leads to another lawsuit
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
Hosted on MSN4d
Why Eli Lilly’s CEO says failing faster is essential to the company’s success
I’m Diane Brady. From transformative weight loss treatment to a potential blockbuster for Alzheimer's, Dave Ricks of Eli ...